Metagenomi Therapeutics (MGX) Operating Margin (2023 - 2026)

Metagenomi Therapeutics (MGX) has reported Operating Margin for 4 consecutive years, with 1970.11% the latest figure, recorded in Q1 2026.

• On a quarterly basis, Operating Margin fell 129601.0% year-over-year to 1970.11% in Q1 2026; TTM through Mar 2026 was 415.48%, a 22174.0% decrease from a year earlier, with the FY2025 full-year figure at 380.85%, down 21085.0% from the prior year.
• Operating Margin was 1970.11% for Q1 2026 at Metagenomi Therapeutics, down from 623.04% in the prior quarter.
• Over five years, Operating Margin peaked at 84.28% in Q2 2024 and troughed at 1970.11% in Q1 2026.
• A 4-year average of 403.12% and a median of 214.51% in 2024 frame the typical range for Operating Margin.
• Across the five-year window, Operating Margin soared 7416 bps in 2024 and slumped 129601 bps in 2026, its largest moves.
• Over 4 years, Operating Margin stood at 162.88% in 2023, then plunged by 32 bps to 214.51% in 2024, then sank by 190 bps to 623.04% in 2025, then plunged by 216 bps to 1970.11% in 2026.
• The last three Operating Margin figures came in at 1970.11% (Q1 2026), 623.04% (Q4 2025), and 263.76% (Q3 2025), per Business Quant data.